Merck (MRK) announced the U.S. FDA has approved enflonsia for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. Enflonsia is a preventive, long-acting monoclonal antibody designed to provide direct, rapid and durable protection through 5 months, a typical RSV season, with the same 105 mg dose regardless of weight. A typical RSV season usually spans autumn to spring of the next year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck Stock (MRK) Slips Despite Positive Clinical Trials Results
- Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics
- Merck announces topline results from Phase 3 CORALreef trials
- Vaccine opponent hired by RFK Jr. searches CDC record for autism link, WSJ says
- Merck call volume above normal and directionally bullish